Thursday, January 27, 2022 11:39:15 AM
I especially like this
What are we invested in an ancient pharma with little pipeline and future headwinds or should our multiple valuation look more like a burgeoning biotech with a deep pipeline and novel approaches to disease with high unmet medical need, very, very high unmet need.
Who knows, the DCVax platform may go along the horizontal growth rate by treating one additional cancer at a time. But what if the platform can also grow along the vertical, has exponential potential. Flipper brought up the idea possibility of treating virus infections. We are talking about DCVax making smarter the most powerful treatment in existence and forever, our immune system. There is "no toxicity" so no limits as a potential treatment option. Sorry, this is over my head a bit, but I have to babble out my excitement.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Closing the Intent-to-Execution Gap May Define Next Wave of AI Investment • WLDS • Feb 17, 2026 9:00 AM
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A • ARWR • Feb 17, 2026 9:00 AM
UPDATE: Hydromer, Inc. Announces Expansion Into High-Speed Automated Coating and UV Cure Equipment Manufacturing • HYDI • Feb 10, 2026 10:58 AM
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System • MWAI • Feb 10, 2026 8:45 AM
LaFleur Minerals Reports Assay Results Highlighting 2.05 g/t Au over 158.25 metres, Confirming Strong Gold Continuity at Swanson Gold Project • LFLRF • Feb 5, 2026 5:29 AM
DRCR Begins Rollout of New Business Model • DRCR • Feb 4, 2026 12:42 PM
